AbbVie Tops Estimates at $17.4 Billion Revenue as Immunology Sales Rise 16%

AbbVie (NYSE: ABBV) reported third-quarter revenue of $17.404 billion, above the $17.35 billion analysts expected, and adjusted diluted EPS of $3.82 against the $3.77 consensus estimate, in an 8-K filed Friday.

On a GAAP basis, diluted EPS was $2.37, compared with $0.10 a year earlier. Worldwide net revenues rose 10.3 percent on a reported basis from $15.776 billion a year earlier.

Immunology and Neuroscience Lead Growth

Global immunology net revenues were $9.165 billion, up 16.3 percent. Skyrizi reached $5.776 billion and Rinvoq $2.706 billion, while Humira fell to $683 million.

Global neuroscience net revenues were $3.389 billion, an increase of 19.4 percent. Botox Therapeutic generated $1.080 billion, Vraylar $1.068 billion and Qulipta $398 million.

Oncology revenues were $1.696 billion, up 0.8 percent, while aesthetics revenues were $1.176 billion, down 1.4 percent.

Raised Guidance and Dividend

AbbVie raised its full-year 2026 adjusted diluted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96. The company said the range includes an unfavorable impact of $0.69 per share from acquired IPR&D and milestones expense incurred through the third quarter. Analysts expected full-year adjusted EPS of $13.95.

The board declared a quarterly dividend of $1.82 per share, up from $1.73, payable in February 2027.

Apogee Acquisition and Pipeline

AbbVie said it completed its acquisition of Apogee Therapeutics, and the company's third-quarter results included acquisition and integration costs of $408 million pre-tax. The company also reported FDA approval of Skyrizi for subcutaneous induction in Crohn's disease and of Juvmo (tavapadon) for Parkinson's disease.

The company's stock last closed at $290.79 on Oct. 29, 2026.